Avoiding Coffee for Atrial Fibrillation
(DECAF Trial)
Trial Summary
What is the purpose of this trial?
Given both the increasing population impact of atrial fibrillation (AF) and the widespread consumption of coffee in society, determining an associated benefit or risk of coffee consumption on AF is of great clinical relevance. This pilot study will evaluate the effect of randomly assigning participants undergoing electrical cardioversion to coffee abstinence or coffee consumption over a 6 month period. This pilot study will provide the first, randomized evaluation of coffee on AF outcomes and will provide important information on whether or not coffee has any effect on AF recurrence.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It mainly focuses on coffee consumption, so it's best to discuss your medications with the study team.
What data supports the effectiveness of the treatment 'Avoid coffee, Consume coffee' for atrial fibrillation?
Is avoiding coffee safe for humans?
How does avoiding or consuming coffee affect atrial fibrillation compared to other treatments?
This treatment is unique because it focuses on the impact of coffee consumption, which is a common dietary habit, rather than using medication or medical procedures. The research suggests that moderate coffee consumption might be associated with a lower risk of atrial fibrillation, but findings are inconsistent, making this approach different from standard medical treatments.23456
Research Team
Chris Wong, MD
Principal Investigator
University of California, San Francisco
Greg Marcus, MD
Principal Investigator
University of California, San Francisco
Eligibility Criteria
This trial is for men and women over 21 who have atrial fibrillation, drink coffee daily, and are scheduled for electrical cardioversion. They must be willing to either abstain from or continue drinking coffee and attend follow-up calls. Exclusions include allergies to coffee, recent heart surgeries, pregnancy plans within six months, or participation in conflicting studies.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomly assigned to either abstain from coffee or continue coffee consumption for up to 6 months
Follow-up
Participants are monitored for safety and effectiveness after treatment, focusing on AF recurrence and other arrhythmias
Treatment Details
Interventions
- Avoid coffee
- Consume coffee
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, San Francisco
Lead Sponsor